Literature DB >> 17189076

Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.

Asa Liljegren Sundberg1, Ann-Charlott Steffen.   

Abstract

PURPOSE: The aim of the present study was to investigate if treatment with lysosomotropic weak bases could increase the intracellular retention of radiohalogens and thereby increase the therapeutic effect of radionuclide tumor targeting. METHODS AND MATERIALS: Four different lysosomotropic bases, chloroquine, ammonium chloride, amantadine, and thioridazine, were investigated for their ability to increase radiohalogen retention in vitro. The two most promising substances, chloroquine and ammonium chloride, were studied in several cell lines (A431, U343MGaCl2:6, SKOV-3, and SKBR-3) in combination with radiolabeled epidermal growth factor (EGF) or the HER2 binding affibody (Z(HER2:4))(2).
RESULTS: The uptake and retention of radionuclides was found to be substantially increased by simultaneous treatment with the lysosomotropic bases. The effect was, however, more pronounced in the epidermal growth factor:epidermal growth factor receptor (EGF:EGFR) system than in the (Z(HER2:4))(2):HER2 system. The therapeutic effect of ammonium chloride treatment combined with (211)At-EGF was also studied. The effect obtained after combined treatment was found to be much better than after (211)At-EGF treatment alone.
CONCLUSIONS: The encouraging results from the present study indicate that the use of lysosomotropic weak bases is a promising approach for increasing the therapeutic effect of radionuclide targeting with radiohalogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17189076     DOI: 10.1016/j.ijrobp.2006.07.1369

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

2.  On the use of chloroquine for chikungunya.

Authors:  Andrea Savarino; Roberto Cauda; Antonio Cassone
Journal:  Lancet Infect Dis       Date:  2007-10       Impact factor: 25.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.